Business
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions
Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in a symposium.1 A total of 40 abstracts will be presented, including
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 REIMAGINE 1–3 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination1","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment2","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"New Ozempic® and Wegovy® data provide further evidence of semaglutide's strong cardiometabolic profile","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":447,"olType":false},{"type":"text","content":"PLAINSBORO, NJ and BAGSVÆRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in a symposium.1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic® and Wegovy® building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions.2","length":824,"tagName":"p"},{"type":"text","content":""The ADA's 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide," said Martin Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. "As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases."","length":572,"tagName":"p"},{"type":"text","content":"On Sunday, June 7, 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conferen...